Singapore markets closed
Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,440.99 +59.64 (+0.71%) Bitcoin USD
62,844.39 +1,495.09 (+2.44%) CMC Crypto 200
1,303.55 -54.45 (-4.01%)
CEL-SCI Corporation (CVM)
NYSE American - Nasdaq Real-time price. Currency in USD
Add to watchlist
As of 09:31AM EDT. Market open.
| Previous close | 1.5100 |
| Open | 1.4500 |
| Bid | 1.5500 x 800 |
| Ask | 1.6400 x 1200 |
| Day's range | 1.5828 - 1.6500 |
| 52-week range | 1.0400 - 3.2300 |
| Volume | |
| Avg. volume | 360,245 |
| Market cap | 86.367M |
| Beta (5Y monthly) | 1.23 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6900 |
| Earnings date | 10 May 2024 - 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 28 Aug 1996 |
| 1y target est | 8.47 |
Business WireCEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
VIENNA, Va., May 08, 2024--CEL-SCI receives FDA go-ahead for its confirmatory study of Multikine in the treatment of head & neck cancer.
Business WireCEL-SCI Appoints Mario Gobbo to Its Board of Directors
VIENNA, Va., April 23, 2024--CEL-SCI appoints Mario Gobbo to its Board of Directors.
Business WireCEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
VIENNA, Va., March 19, 2024--CEL-SCI’s LEAPS vaccine offers promising new paradigm to treat rheumatoid arthritis: published in Frontiers in Immunology.
© 2024 Yahoo. All rights reserved.